Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)
Esther Natalie Olíva(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Francesco Nobile(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Roberto Latagliata(Ospedale di Belcolle), Grazia Sanpaolo(Casa Sollievo della Sofferenza), Francesco Di Raimondo(University of Catania), Filippo Rodà(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Francesca Ronco(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Giuseppe A. Palumbo(University of Catania), Maria Teresa Voso(University of Rome Tor Vergata), Gina Zini(Università Cattolica del Sacro Cuore), Silvia Finotto(Istituto Oncologico Veneto), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Antonella Poloni(Marche Polytechnic University), Valeria Santini(Azienda Ospedaliero-Universitaria Careggi), Antonio Marino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Pietro Leoni(Azienda Ospedaliero-Universitaria delle Marche), Caterina Alati(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Giuliana Alimena(Thrombolysis in Myocardial Infarction Study Group), Alfredo Molteni(Istituti Ospitalieri di Cremona)
Cited by 18
Related Papers
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553